Effects of captopril (SQ 14,225) in a patient with primary pulmonary hypertension

J. D. HOROWITZ
M.B. B.S., F.R.A.C.P.

L. E. OLIVER
M.B. B.S., F.R.A.C.P.

A. J. GOBLE
M.D., F.R.C.P., F.R.A.C.P.

J. B. BRENNAN
M.B. B.S., F.R.A.C.P.

D. HARDING
M.B. B.S., F.R.C.P., F.R.A.C.P.

W. J. LOUIS
M.B. B.S., F.R.A.C.P.

Departments of Cardiology, Medicine and Clinical Pharmacology,
Austin Hospital, Melbourne

Summary
In a 33-year-old patient with severe primary pulmonary hypertension, the acute administration of the angiotensin-converting-enzyme inhibitor captopril (SQ 14,225) induced a rise in cardiac output, and a fall in both pulmonary and systemic vascular resistance. Subsequent chronic oral administration of captopril induced only transient clinical improvement, and the patient died. Captopril may nevertheless be useful in the treatment of less advanced cases of this disease.

Case report
A 33-year-old married woman with 2 children was admitted to hospital in February, 1979 for management of right heart failure due to primary pulmonary hypertension. There was a past history of Raynaud’s phenomenon and mild systemic hypertension. Oral contraceptives had last been used 18 months previously.

Exertional dyspnoea had been present for 15 months. Physical examination revealed signs of severe pulmonary hypertension with no evidence of intracardiac shunt. Pulmonary arteriography in September 1978 revealed no evidence of embolic disease. The pulmonary artery pressure was 70/32 mmHg (mean 50 mm). Pulmonary artery saturation was 53%.

The patient’s course between April 1978 and February 1979 was marked by gradual clinical deterioration with incapacitating dyspnoea on minimal exertion and stress.

On examination in February 1979 she was dyspnoeic at rest, with central cyanosis. Systemic BP was 80/50 mmHg, and the jugular venous pressure was elevated 15 cm. There was poor peripheral perfusion, with a prominent right ventricular impulse and a left parasternal fourth heart sound. Hepatomegaly, gross ascites, and peripheral oedema were present.

The patient was treated with bed rest, frusemide (40 mg/day) and amiloride (5 mg twice/day). Chest X-ray showed cardiomegaly with a large right ventricle and oligaemic lung fields. Haemoglobin was 14-9 g/dl with normal white cell and platelet counts. Arterial blood gases (while breathing air) were $P_{O_2}$ 35; $P_{CO_2}$ 34; pH 7-39.

In view of the patient’s deteriorating clinical status, a trial of captopril (SQ 14,225) was arranged. Informed consent was obtained, and treatment with indomethacin (125 mg/day) was commenced before the initiation of treatment with captopril.

A Swan-Ganz thermodilution catheter was inserted for monitoring of the haemodynamic effects before and after the initial dose of captopril (6 mg). These are summarized in Table 1. Valid pulmonary wedge pressure tracings could not be obtained. The maximum increase in cardiac output occurred 1-25 hr after the administration of captopril and persisted for 2-5 hr. A subsequent dose of 12-5 mg failed to produce a further response.

In view of the acute response to oral captopril, long-term treatment was commenced, in a dose of 12-5 mg 8-hourly. There was some reduction in dyspnoea at rest, and the patient became less cyanosed, with a concomitant improvement in hypoxaemia ($P_{O_2}$ 53; $P_{CO_2}$ 34; pH, 7-51 while...
The present report is the first one of the use of captopril for this clinical condition. The patient was unfortunately in a moribund state at the start of the study, with clinical evidence of gross right heart failure associated with gross depression of cardiac output. Captopril was made available on the condition that the patient be pre-treated with indomethacin, because of fears of a possible bronchoconstrictor effect mediated by kinin and prostaglandin release (Greenberg et al., 1979). However, it is also possible that the pulmonary vasodilator effects of captopril which might be mediated by prostacyclin release, were significantly attenuated by indomethacin (Murthy, Waldrong and Goldberg, 1978).

Acute administration of a very small dose of captopril was associated with a rise in cardiac output, and a fall in both pulmonary and systemic vascular resistance. Prolonged oral administration of captopril induced minor reduction in dyspnoea and improvement in hypoxaemia. However, these limited results suggest that further investigation of the effects of captopril in patients with primary pulmonary hypertension appears to be justified.

Acknowledgments
We would like to thank Dr J. Carson of E. R. Squibb (Australia) for arranging the availability of captopril, and Dr G. Dusting for his helpful comments.

References